FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

Table 1 Baseline characteristics of all patients, n (%)

Characteristics	FOLFIRINOX (n = 86)	Gem + Nab-paclitaxel (n = 81)	P value
Age (yr)	54 (30-78)	65 (42-79)	< 0.001
Male sex	49 (57.0)	37 (45.7)	0.144
ECOG-PS			0.040
0	72 (83.7)	57 (70.4)
1	14 (16.3)	24 (29.6)
Body mass index	22.13 (16.49-31.63)	21.97 (16.11-29.59)	0.432
Tumor location1			0.398
Head and neck	40 (46.5)	32 (39.5)
Body and tail	46 (53.5)	48 (49.3)
Metastasis site
Liver	57 (66.3)	40 (49.4)	0.027
Lung	9 (10.5)	12 (14.8)	0.397
Bone	4 (4.7)	6 (7.4)	0.5262
Peritoneum (carcinomatosis)	35 (40.7)	42 (51.9)	0.148
Distant LN	33 (38.4)	28 (34.6)	0.610
Othersite (e.g. adrenal gland)	14 (16.3)	20 (24.7)	0.177
No. of metastasis site			0.726
1 site	39 (45.3)	38 (46.9)
2 sites	30 (34.9)	24 (29.6)
3 or more	17 (19.8)	19 (23.5)
Laboratory data (at diagnosis)
WBC count (cells/μL)	6765 (2830-21880)	6240 (2580-12240)	0.068
Neutrophil count (cells/μL)	4660 (1610-18930)	4045 (1410-8540)	0.035
Prothrombin time (INR)	1.01 (0.80-1.28)	1.00 (0.83-1.16)	0.176
Total bilirubin (mg/dL)	0.7 (0.2-13.5)	0.6 (0.2-23.4)	0.200
AST (IU/L)	24 (9-204)	22 (9-765)	0.286
ALT (IU/L)	27 (5-192)	17 (5-717)	0.117
Alkaline phosphatase (IU/L)	116 (43-957)	92 (37-2080)	0.798
CA 19-9 at diagnosis (U/mL)	585.3 (3.4-20000)	305.2 (0.6-20000)	0.678

¹Except for one case that originated from an ectopic pancreas;

²Fisher's exact test. Gem + nabPTX: Gemcitabine plus nab-paclitaxel; ECOG-PS: Eastern Cooperative Oncology Group performance status; LN: Lymph node; WBC: White blood cell; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CA: Carbohydrate antigen.